Drug Trial Radar · NCT02760277
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 28, 2016
Primary completion
Apr 26, 2018
Study completion Apr 26, 2018
Sponsor
- Lead sponsor
- ReveraGen BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Pittsburgh; National Institute of Neurological Disorders and Stroke (NINDS); Cooperative International Neuromuscular Research Group; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- First posted
- May 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 4 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/day/dayDrug
Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Vamorolone 0.75 mg/day/dayDrug
Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Vamorolone 2.0 mg/day/dayDrug
Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Vamorolone 6.0 mg/day/dayDrug
Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 weeks
- Total Number of Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 weeks
- Muscle Function Measured by Time to Stand Test (TTSTAND)- VelocityTime frame: 002 Baseline, 003 Baseline, 003 Week 12, Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
- BMI Z-scoreTime frame: 002 Baseline, 003 Week 12, Week 24
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
University of California Davis
Davis, California
University of Florida
Gainesville, Florida
Nemours Children's Hospital
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
Duke University
Durham, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Royal Children's Hospital
Melbourne, Australia
Sydney Children's Hospital
Westmead, Australia
Alberta Children's Hospital
Calgary, Alberta, Canada
Schneider Children's Medical Center
Petah Tikva, Israel
Queen Silvia Children's Hospital
Gothenburg, Sweden
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.